Post-Sinus Surgery Recovery

About Oticara

Oticara is pioneering a targeted, physician-delivered treatment for chronic rhinosinusitis (CRS) using a novel intranasal corticosteroid cream. The company's lead program has demonstrated positive Phase 2 results, showing durable symptom improvement in hard-to-treat, post-surgical patients. By localizing a potent steroid directly to the site of disease with a single in-office dose, Oticara aims to maximize efficacy while minimizing systemic exposure and simplifying the treatment regimen. The company is privately held, led by experienced pharmaceutical executives, and is advancing a pipeline that includes both CRS symptom management and post-surgical recovery programs.

Therapeutic Areas